Royalty Pharma Declares Third-Quarter 2021 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved a third-quarter dividend of $0.17 per Class A ordinary share. This dividend will be paid on September 15, 2021, to shareholders on record by the close of business on August 20, 2021. Royalty Pharma is a leading buyer of biopharmaceutical royalties and funds innovation across the biopharmaceutical industry, holding royalties for over 45 commercial products, including well-known therapies like Imbruvica and Xtandi.
- Approval of $0.17 dividend per Class A share enhances shareholder income.
- Strong portfolio with royalties on over 45 commercial products indicates robust revenue potential.
- None.
NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of
The dividend will be paid on September 15, 2021, to shareholders of record at the close of business on August 20, 2021.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, J&J’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
What is the dividend amount announced by Royalty Pharma (RPRX) for Q3 2021?
When will Royalty Pharma (RPRX) pay the Q3 2021 dividend?
What is the record date for the Royalty Pharma (RPRX) Q3 2021 dividend?
How many commercial products does Royalty Pharma (RPRX) hold royalties on?
